Concert Pharmaceuticals Inc. (Nasdaq: CNCE) was not granted a Post Grant Review petition challenging the validity of an Incyte Pharmaceutical (Nasdaq: INCY) patent. Shares of Concert Pharmaceuticals plummeted $7.53 to close at $20.15 while Incyte Pharmaceuticals stock gained $1.01 to close at $94.07.